Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Australia.
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
Diabetes Care. 2015 Mar;38(3):521-8. doi: 10.2337/dc14-0180. Epub 2014 Dec 18.
People with diabetes frequently develop vascular disease. We investigated the relationship between blood 25-hydroxyvitamin D (25OH-D) concentration and vascular disease risk in type 2 diabetes.
The relationships between blood 25OH-D concentration at baseline and the incidence of macrovascular (including myocardial infarction and stroke) and microvascular (retinopathy, nephropathy, neuropathy, and amputation) disease were analyzed with Cox proportional hazards models and logistic regression in an observational study of patients in the 5-year Fenofibrate Intervention and Event Lowering in Diabetes trial.
A total of 50% of the patients had low vitamin D concentrations, as indicated by median blood 25OH-D concentration of 49 nmol/L. These patients with a blood 25OH-D concentration <50 nmol/L had a higher cumulative incidence of macrovascular and microvascular events than those with levels ≥50 nmol/L. Multivariate analysis, stratified by treatment and adjusted for relevant confounders, identified blood 25OH-D concentration as an independent predictor of macrovascular events. A 50 nmol/L difference in blood 25OH-D concentration was associated with a 23% (P = 0.007) change in risk of macrovascular complications during the study, and further adjustments for seasonality, hs-CRP, and physical activity level had little impact. The unadjusted risk of microvascular complications was 18% (P = 0.006) higher during the study, though the excess risk declined to 11-14% and lost significance with adjustment for HbA1c, seasonality, or physical activity.
Low blood 25OH-D concentrations are associated with an increased risk of macrovascular and microvascular disease events in type 2 diabetes. However, a causal link remains to be demonstrated.
糖尿病患者常发生血管疾病。我们研究了 2 型糖尿病患者血 25-羟维生素 D(25OH-D)浓度与血管疾病风险之间的关系。
在一项为期 5 年的非诺贝特干预和糖尿病事件降低(Fenofibrate Intervention and Event Lowering in Diabetes,FIELD)试验的观察性研究中,采用 Cox 比例风险模型和逻辑回归分析了基线时血 25OH-D 浓度与大血管(包括心肌梗死和中风)和微血管(视网膜病变、肾病、神经病变和截肢)疾病发生率之间的关系。
共有 50%的患者维生素 D 浓度较低,血 25OH-D 中位数浓度为 49 nmol/L。与血 25OH-D 浓度≥50 nmol/L 的患者相比,血 25OH-D 浓度<50 nmol/L 的患者大血管和微血管事件的累积发生率更高。多变量分析,按治疗分层,并校正相关混杂因素,发现血 25OH-D 浓度是大血管事件的独立预测因素。血 25OH-D 浓度相差 50 nmol/L,与研究期间大血管并发症风险增加 23%(P=0.007)相关,进一步调整季节性、hs-CRP 和身体活动水平对结果影响不大。微血管并发症的未校正风险在研究期间增加了 18%(P=0.006),但随着 HbA1c、季节性或身体活动的调整,超额风险下降至 11-14%且失去统计学意义。
2 型糖尿病患者血 25OH-D 浓度较低与大血管和微血管疾病事件风险增加相关。然而,因果关系仍有待证实。